<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32574550</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2046-2441</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Open biology</Title><ISOAbbreviation>Open Biol</ISOAbbreviation></Journal><ArticleTitle>An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease.</ArticleTitle><Pagination><StartPage>200116</StartPage><MedlinePgn>200116</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">200116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1098/rsob.200116</ELocationID><Abstract><AbstractText>Biomarkers for amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) are currently not clinically available for disease diagnosis or analysis of disease progression. If identified, biomarkers could improve patient outcomes by enabling early intervention and assist in the determination of treatment efficacy. We hypothesized that neural-enriched extracellular vesicles could provide microRNA (miRNA) fingerprints with unequivocal signatures of neurodegeneration. Using blood plasma from ALS/MND patients and controls, we extracted neural-enriched extracellular vesicle fractions and conducted next-generation sequencing and qPCR of miRNA components of the transcriptome. We here report eight miRNA sequences which significantly distinguish ALS/MND patients from controls in a replicated experiment using a second cohort of patients and controls. miRNA sequences from patient blood samples using neural-enriched extracellular vesicles may yield unique insights into mechanisms of neurodegeneration and assist in early diagnosis of ALS/MND.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Banack</LastName><ForeName>Sandra Anne</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Brain Chemistry Labs, Institute for Ethnomedicine, PO Box 3464, Jackson, WY 83001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunlop</LastName><ForeName>Rachael Anne</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Brain Chemistry Labs, Institute for Ethnomedicine, PO Box 3464, Jackson, WY 83001, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Paul Alan</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Brain Chemistry Labs, Institute for Ethnomedicine, PO Box 3464, Jackson, WY 83001, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Open Biol</MedlineTA><NlmUniqueID>101580419</NlmUniqueID><ISSNLinking>2046-2441</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005819">Genetic Markers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016172" MajorTopicYN="N">DNA Fingerprinting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067128" MajorTopicYN="N">Extracellular Vesicles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005819" MajorTopicYN="N">Genetic Markers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS/MND</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">exosomes</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword></KeywordList><CoiStatement>The Brain Chemistry Labs is filing a patent on the use of this biomarker.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32574550</ArticleId><ArticleId IdType="pmc">PMC7333885</ArticleId><ArticleId IdType="doi">10.1098/rsob.200116</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hosaka T, Yamashita T, Tamaoka A, Kwak S. 2019. Extracellular RNAs as biomarkers of sporadic amyotrophic lateral sclerosis and other neurodegenerative diseases. Int. J. Mol. Sci. 20, 3148 (10.3390/ijms20133148)</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133148</ArticleId><ArticleId IdType="pmc">PMC6651127</ArticleId><ArticleId IdType="pubmed">31252669</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine TD, et al. . 2017. Phase I clinical trial of safety of L-serine for ALS patients. Amyotroph. Lateral Scler. Front. Degener. 18, 107&#x2013;111. (10.1080/21678421.2016.1221971)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1221971</ArticleId><ArticleId IdType="pubmed">27589995</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, et al. . 2006. Identification of potential CSF biomarkers in ALS. Neurology 66, 1218&#x2013;1222. (10.1212/01.wnl.0000203129.82104.07)</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203129.82104.07</ArticleId><ArticleId IdType="pubmed">16481598</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clinic. 2019. 
Amyotrophic lateral sclerosis (ALS): diagnosis and treatment. See https://www.mayoclinic.org/diseases-conditions/amyotrophic-lateral-sclerosis/diagnosis-treatment/drc-20354027 (accessed on 27 April 2020).</Citation></Reference><Reference><Citation>Ferrarese C, et al. . 2001. Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis. Neurology 56, 270&#x2013;272. (10.1212/WNL.56.2.270)</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.56.2.270</ArticleId><ArticleId IdType="pubmed">11160972</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, et al. . 2015. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: Insights from a longitudinal study. J. Neurol. Neurosurg. Psychiatry 86, 565&#x2013;573. (10.1136/jnnp-2014-307672)</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. 2016. Rate of disease progression: a prognostic biomarker in ALS. J. Neurol. Neurosurg. Psychiatry 87, 628&#x2013;632. (10.1136/jnnp-2015-310998)</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, Schultz D, Benatar M, Rogers ML. 2017. Urinary p75ECD: a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology 88, 1137&#x2013;1143. (10.1212/WNL.0000000000003741)</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P.. 2019. Diagnostic and prognostic performance of neurofilaments in ALS. Front. Neurol. 9, 1167 (10.3389/fneur.2018.01167)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH. 2004. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62, 1758&#x2013;1765. (10.1212/WNL.62.10.1758)</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.62.10.1758</ArticleId><ArticleId IdType="pubmed">15159474</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, Borchelt D, Shaw G. 2009. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J. Neurochem. 111, 1182&#x2013;1191. (10.1111/j.1471-4159.2009.06386.x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06386.x</ArticleId><ArticleId IdType="pubmed">19765193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson ME, Boumaza I, Lacomis D, Bowser R. 2010. Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS ONE 5, e15133 (10.1371/journal.pone.0015133)</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015133</ArticleId><ArticleId IdType="pmc">PMC3000338</ArticleId><ArticleId IdType="pubmed">21151566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Bokde ALW, Byrne S, Elamin M, Fagan AJ, Hardiman O. 2012. Spinal cord markers in ALS: diagnostic and biomarker considerations. Amyotroph. Lateral Scler. 13, 407&#x2013;415. (10.3109/17482968.2011.649760)</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.649760</ArticleId><ArticleId IdType="pubmed">22329869</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, et al. . 2012. Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph. Lateral Scler. 13, 439&#x2013;445. (10.3109/17482968.2012.688837)</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.688837</ArticleId><ArticleId IdType="pmc">PMC3422377</ArticleId><ArticleId IdType="pubmed">22670883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasiuk J, Ku&#x142;akowska A, Drozdowski W, Kornhuber J, Lewczuk P. 2012. CSF markers in amyotrophic lateral sclerosis. J. Neural Transm. 119, 747&#x2013;757. (10.1007/s00702-012-0806-y)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-012-0806-y</ArticleId><ArticleId IdType="pubmed">22555610</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Steinacker P, Lehnert S, Schneider A, Walther P, Thal DR, Linsenmeier M, Ludolph AC, Otto M. 2014. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph. Lateral Scler. Front. Degener. 15, 351&#x2013;356. (10.3109/21678421.2014.905606)</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.905606</ArticleId><ArticleId IdType="pubmed">24834468</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, et al. . 2015. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84, 2247&#x2013;2257. (10.1212/WNL.0000000000001642)</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>von Neuhoff N, et al. 2012. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS ONE 7, e44401 (10.1371/journal.pone.0044401)</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044401</ArticleId><ArticleId IdType="pmc">PMC3435306</ArticleId><ArticleId IdType="pubmed">22970211</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegtel DM, Gould SJ. 2019. Exosomes. Annu. Rev. Biochem. 88, 487&#x2013;514. (10.1146/annurev-biochem-013118-111902)</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-013118-111902</ArticleId><ArticleId IdType="pubmed">31220978</ArticleId></ArticleIdList></Reference><Reference><Citation>Th&#xe9;ry C, et al. . 2018. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (10.1080/20013078.2018.1535750)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20013078.2018.1535750</ArticleId><ArticleId IdType="pmc">PMC6322352</ArticleId><ArticleId IdType="pubmed">30637094</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheruiyot C, Pataki Z, Ramratnam B, Li M. 2018. Proteomic analysis of exosomes and its application in HIV-1 infection. Proteomics Clin. Appl. 12, 1700142 (10.1002/prca.201700142)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.201700142</ArticleId><ArticleId IdType="pubmed">29687643</ArticleId></ArticleIdList></Reference><Reference><Citation>Manna I, et al. . 2018. Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. FASEB J. 32, 4241&#x2013;4246. (10.1096/fj.201701533R)</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201701533R</ArticleId><ArticleId IdType="pubmed">29505299</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y, Sun J, Wang X, Hu T, Ma Y, Kong C, Piao H, Yu T, Zhang G. 2019. Exosomes: a promising avenue for the diagnosis of breast cancer. Technol. Cancer Res. Treat. 18, 1533033818821421 (10.1177/1533033818821421)</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533033818821421</ArticleId><ArticleId IdType="pmc">PMC6373987</ArticleId><ArticleId IdType="pubmed">30760122</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Jiang Y, Yang L, Yan S, Wang Y-G, Lu X-J. 2018. Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. J. Cell. Biochem. 119, 4711&#x2013;4716. (10.1002/jcb.26650)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.26650</ArticleId><ArticleId IdType="pubmed">29278659</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Xia Z, Deng YN, Yang Y, Zhang P, Zhu H, Xu N, Liang S. 2019. Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol. 9, 180212 (10.1098/rsob.180212)</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.180212</ArticleId><ArticleId IdType="pmc">PMC6367136</ArticleId><ArticleId IdType="pubmed">30958116</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HZY, Ong KL, Seeher K, Armstrong NJ, Thalamuthu A, Brodaty H, Sachdev P, Mather K. 2015. Circulating microRNAs as biomarkers of Alzheimer's disease: a systematic review. J. Alzheimer's Dis. 49, 755&#x2013;766. (10.3233/JAD-150619)</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150619</ArticleId><ArticleId IdType="pubmed">26484928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Zhang Y, Yue P, Liu L, Wang C, Zhou K, Hua Y, Wu G, Li Y. 2019. Diagnostic significance of circulating miRNAs in systemic lupus erythematosus. PLoS ONE 14, e0217523 (10.1371/journal.pone.0217523)</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0217523</ArticleId><ArticleId IdType="pmc">PMC6548426</ArticleId><ArticleId IdType="pubmed">31163082</ArticleId></ArticleIdList></Reference><Reference><Citation>Atif H, Hicks SD. 2019. A review of MicroRNA biomarkers in traumatic brain injury. J. Exp. Neurosci. 13, 117906951983228 (10.1177/1179069519832286)</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1179069519832286</ArticleId><ArticleId IdType="pmc">PMC6410383</ArticleId><ArticleId IdType="pubmed">30886525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou SS, Jin JP, Wang JQ, Zhang ZG, Freedman JH, Zheng Y, Cai L. 2018. MiRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges review-article. Acta Pharmacol. Sin. 39, 1073&#x2013;1084. (10.1038/aps.2018.30)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2018.30</ArticleId><ArticleId IdType="pmc">PMC6289363</ArticleId><ArticleId IdType="pubmed">29877320</ArticleId></ArticleIdList></Reference><Reference><Citation>Roser AE, Caldi Gomes L, Sch&#xfc;nemann J, Maass F, Lingor P. 2018. Circulating miRNAs as diagnostic biomarkers for Parkinson's disease. Front. Neurosci. 12, 625 (10.3389/fnins.2018.00625)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00625</ArticleId><ArticleId IdType="pmc">PMC6135037</ArticleId><ArticleId IdType="pubmed">30233304</ArticleId></ArticleIdList></Reference><Reference><Citation>Piket E, Zheleznyakova GY, Kular L, Jagodic M. 2019. Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: a comprehensive overview. J. Autoimmun. 101, 17&#x2013;25. (10.1016/j.jaut.2019.04.002)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.04.002</ArticleId><ArticleId IdType="pubmed">31014917</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaishya S, Sarwade RD, Seshadri V. 2018. MicroRNA, proteins, and metabolites as novel biomarkers for prediabetes, diabetes, and related complications. Front. Endocrinol. (Lausanne) 9, 180 (10.3389/fendo.2018.00180)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00180</ArticleId><ArticleId IdType="pmc">PMC5925339</ArticleId><ArticleId IdType="pubmed">29740397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustapic M, Eitan E, Werner JKJ, Berkowitz ST, Lazaropoulos MP, Tran J, Goetzl EJ, Kapogiannis D. 2017. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front. Neurosci. 11, 278 (10.3389/FNINS.2017.00278)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FNINS.2017.00278</ArticleId><ArticleId IdType="pmc">PMC5439289</ArticleId><ArticleId IdType="pubmed">28588440</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. 2000. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 1, 293&#x2013;299. (10.1080/146608200300079536)</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>GTEx Portal. 2019 Gene expression for L1CAM. See https://www.gtexportal.org/home/gene/ENSG00000198910 (accessed on 22 January 2020).</Citation></Reference><Reference><Citation>Martin M. 2011. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10 (10.14806/ej.17.1.200)</Citation><ArticleIdList><ArticleId IdType="doi">10.14806/ej.17.1.200</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357&#x2013;359. (10.1038/nmeth.1923)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1923</ArticleId><ArticleId IdType="pmc">PMC3322381</ArticleId><ArticleId IdType="pubmed">22388286</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, McCarthy DJ, Smyth GK. 2009. edgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139&#x2013;140. (10.1093/bioinformatics/btp616)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId><ArticleId IdType="pmc">PMC2796818</ArticleId><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson MD, Oshlack A. 2010. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (10.1186/gb-2010-11-3-r25)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2010-11-3-r25</ArticleId><ArticleId IdType="pmc">PMC2864565</ArticleId><ArticleId IdType="pubmed">20196867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozomara A, Griffiths-Jones S. 2014. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68&#x2013;D73. (10.1093/nar/gkt1181)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1181</ArticleId><ArticleId IdType="pmc">PMC3965103</ArticleId><ArticleId IdType="pubmed">24275495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bustin SA, et al. . 2009. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611&#x2013;622. (10.1373/clinchem.2008.112797)</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2008.112797</ArticleId><ArticleId IdType="pubmed">19246619</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen CL, Jensen JL, &#xd8;rntoft TF. 2004. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64, 5245&#x2013;5250. (10.1158/0008-5472.CAN-04-0496)</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-04-0496</ArticleId><ArticleId IdType="pubmed">15289330</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F.. 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (10.1186/gb-2002-3-7-research0034)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2002-3-7-research0034</ArticleId><ArticleId IdType="pmc">PMC126239</ArticleId><ArticleId IdType="pubmed">12184808</ArticleId></ArticleIdList></Reference><Reference><Citation>Witwer KW, et al. . 2013. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2, 20360 (10.3402/jev.v2i0.20360)</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jev.v2i0.20360</ArticleId><ArticleId IdType="pmc">PMC3760646</ArticleId><ArticleId IdType="pubmed">24009894</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AF, Pegtel DM, Lambertz U, Leonardi T, O'Driscoll L, Pluchino S, Ter-Ovanesyan D, Nolte-&#x2018;t Hoen ENM. 2013. ISEV position paper: extracellular vesicle RNA analysis and bioinformatics. J. Extracell. Vesicles 2, 22859 (10.3402/jev.v2i0.22859)</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/jev.v2i0.22859</ArticleId><ArticleId IdType="pmc">PMC3873759</ArticleId><ArticleId IdType="pubmed">24376909</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsu M, Hama Y, Utsumi J, Takashina K, Yasumatsu H, Mori F, Wakabayashi K, Shoji M, Sasaki H. 2019. MicroRNA expression profiles of neuron-derived extracellular vesicles in plasma from patients with amyotrophic lateral sclerosis. Neurosci. Lett. 708, 134176 (10.1016/j.neulet.2019.03.048)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.03.048</ArticleId><ArticleId IdType="pubmed">31173847</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, et al. . 2012. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 122, 3063&#x2013;3087. (10.1172/JCI62636)</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62636</ArticleId><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B, Guida M, Guida M, Coppola C, De Mieri G, Cotrufo R.. 2012. A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 508, 35&#x2013;40. (10.1016/j.gene.2012.07.058)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2012.07.058</ArticleId><ArticleId IdType="pubmed">22903028</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, et al. . 2017. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol. Aging 55, 123&#x2013;131. (10.1016/j.neurobiolaging.2017.03.027)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.03.027</ArticleId><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Liguori M, Nuzziello N, Introna A, Consiglio A, Licciulli F, D'Errico E, Scarafino A, Distaso E, Simone IL. 2018. Dysregulation of microRNAs and target genes networks in peripheral blood of patients with sporadic amyotrophic lateral sclerosis. Front. Mol. Neurosci. 11, 288 (10.3389/fnmol.2018.00288)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00288</ArticleId><ArticleId IdType="pmc">PMC6121079</ArticleId><ArticleId IdType="pubmed">30210287</ArticleId></ArticleIdList></Reference><Reference><Citation>Raheja R, et al. . 2018. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve 58, 261&#x2013;269. (10.1002/mus.26106)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26106</ArticleId><ArticleId IdType="pmc">PMC6103911</ArticleId><ArticleId IdType="pubmed">29466830</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrabec K, Bo&#x161;tjan&#x10d;i&#x10d; E, Koritnik B, Leonardis L, Dolenc Gro&#x161;elj L, Zidar J, Rogelj B, Glava&#x10d; D, Ravnik-Glava&#x10d; M. 2018. Differential expression of several miRNAs and the host genes AATK and DNM2 in leukocytes of sporadic ALS patients. Front. Mol. Neurosci. 11, 106 (10.3389/fnmol.2018.00106)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00106</ArticleId><ArticleId IdType="pmc">PMC5893848</ArticleId><ArticleId IdType="pubmed">29670510</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B, et al. . 2014. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics 15, 243&#x2013;253. (10.1007/s10048-014-0420-2)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-014-0420-2</ArticleId><ArticleId IdType="pubmed">25130371</ArticleId></ArticleIdList></Reference><Reference><Citation>Toivonen JM, Manzano R, Oliv&#xe1;n S, Zaragoza P, Garc&#xed;a-Redondo A, Osta R. 2014. MicroRNA-206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS ONE 9, e89065 (10.1371/journal.pone.0089065)</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089065</ArticleId><ArticleId IdType="pmc">PMC3930686</ArticleId><ArticleId IdType="pubmed">24586506</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi I, Hama Y, Matsushima M, Hirotani M, Kano T, Hohzen H, Yabe I, Utsumi J, Sasaki H. 2015. Identification of plasma microRNAs as a biomarker of sporadic amyotrophic lateral sclerosis. Mol. Brain 8, 67 (10.1186/s13041-015-0161-7)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-015-0161-7</ArticleId><ArticleId IdType="pmc">PMC4619470</ArticleId><ArticleId IdType="pubmed">26497046</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Wei Q, Chen X, Li C, Cao B, Ou R, Hadano S, Shang H-F. 2016. Aberration of miRNAs expression in leukocytes from sporadic amyotrophic lateral sclerosis. Front. Mol. Neurosci. 9, 69 (10.3389/fnmol.2016.00069)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2016.00069</ArticleId><ArticleId IdType="pmc">PMC4987348</ArticleId><ArticleId IdType="pubmed">27582688</ArticleId></ArticleIdList></Reference><Reference><Citation>de Andrade HMT, de Albuquerque M, Avansini SH, de Rocha SC, Dogini DB, Nucci A, Carvalho B, Lopes-Cendes I. 2016. MicroRNAs-424 and 206 are potential prognostic markers in spinal onset amyotrophic lateral sclerosis. J. Neurol. Sci. 368, 19&#x2013;24. (10.1016/j.jns.2016.06.046)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2016.06.046</ArticleId><ArticleId IdType="pubmed">27538595</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasca E, Pegoraro V, Merico A, Angelini C. 2016. Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin. Neuropathol. 35, 22&#x2013;30. (10.5414/NP300889)</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP300889</ArticleId><ArticleId IdType="pubmed">26588026</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheinerman KS, et al. . 2017. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimer's Res. Ther. 9, 1&#x2013;13. (10.1186/s13195-017-0316-0)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-017-0316-0</ArticleId><ArticleId IdType="pmc">PMC5679501</ArticleId><ArticleId IdType="pubmed">29121998</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R, Wyles M, Heath PR, Kazoka M, Wollff H, Shaw PJ, Kirby J. 2018. Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs related to neural and glial activity. Front. Neurosci. 11, 731 (10.3389/fnins.2017.00731)</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00731</ArticleId><ArticleId IdType="pmc">PMC5767269</ArticleId><ArticleId IdType="pubmed">29375285</ArticleId></ArticleIdList></Reference><Reference><Citation>Benoist M, Palenzuela R, Rozas C, Rojas P, Tortosa E, Morales B, Gonz&#xe1;lez-Billault C, &#xc1;vila J, Esteban JA. 2013. MAP1B-dependent Rac activation is required for AMPA receptor endocytosis during long-term depression. EMBO J. 32, 2287&#x2013;2299. (10.1038/emboj.2013.166)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.166</ArticleId><ArticleId IdType="pmc">PMC3746201</ArticleId><ArticleId IdType="pubmed">23881099</ArticleId></ArticleIdList></Reference><Reference><Citation>Etzrodt M, et al. . 2012. Regulation of monocyte functional heterogeneity by miR-146a and Relb. Cell Rep. 1, 317&#x2013;324. (10.1016/j.celrep.2012.02.009)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.02.009</ArticleId><ArticleId IdType="pmc">PMC3334310</ArticleId><ArticleId IdType="pubmed">22545247</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YL, Shen CKJ. 2013. Modulation of mGluR-dependent MAP1B translation and AMPA receptor endocytosis by microRNA miR-146a-5p. J. Neurosci. 33, 9013&#x2013;9020. (10.1523/JNEUROSCI.5210-12.2013)</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5210-12.2013</ArticleId><ArticleId IdType="pmc">PMC6705019</ArticleId><ArticleId IdType="pubmed">23699512</ArticleId></ArticleIdList></Reference><Reference><Citation>Sison SL, Patitucci TN, Seminary ER, Villalon E, Lorson CL, Ebert AD. 2017. Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy. Hum. Mol. Genet. 26, 3409&#x2013;3420. (10.1093/hmg/ddx230)</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx230</ArticleId><ArticleId IdType="pubmed">28637335</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Cao DL, Jiang BC, Yang T, Gao YJ. 2015. MicroRNA-146a-5p attenuates neuropathic pain via suppressing TRAF6 signaling in the spinal cord. Brain. Behav. Immun. 49, 119&#x2013;129. (10.1016/j.bbi.2015.04.018)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2015.04.018</ArticleId><ArticleId IdType="pubmed">25957028</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A, Zurolo E, Prabowo A, Fluiter K, Spliet WGM, van Rijen PC, Gorter JA, Aronica E.. 2012. MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory response. PLoS ONE 7, e44789 (10.1371/journal.pone.0044789)</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044789</ArticleId><ArticleId IdType="pmc">PMC3441440</ArticleId><ArticleId IdType="pubmed">23028621</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu WD, Lu MM, Pan HF, Ye DQ. 2012. Association of microRNA-146a with autoimmune diseases. Inflammation 35, 1525&#x2013;1529. (10.1007/s10753-012-9467-0)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-012-9467-0</ArticleId><ArticleId IdType="pubmed">22535496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ. 2010. Differential regulation of Interleukin-1 receptor-associated Kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-&#x3ba;B in stressed human astroglial cells and in Alzheimer disease. J. Biol. Chem. 285, 38 951&#x2013;38 960. (10.1074/jbc.M110.178848)</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.178848</ArticleId><ArticleId IdType="pmc">PMC2998119</ArticleId><ArticleId IdType="pubmed">20937840</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogswell JP, et al. . 2008. Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimer's Dis. 14, 27&#x2013;41. (10.3233/JAD-2008-14103)</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2008-14103</ArticleId><ArticleId IdType="pubmed">18525125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi P, Lukiw WJ. 2009. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci. Lett. 459, 100&#x2013;104. (10.1016/j.neulet.2009.04.052)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2009.04.052</ArticleId><ArticleId IdType="pubmed">19406203</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T. 2014. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J. Alzheimer's Dis. 39, 253&#x2013;259. (10.3233/JAD-130932)</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130932</ArticleId><ArticleId IdType="pubmed">24157723</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, Kuiperij HB, Claassen JA, K&#xfc;sters B, Verbeek MM. 2014. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol. Aging 35, 152&#x2013;158. (10.1016/j.neurobiolaging.2013.07.005)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.005</ArticleId><ArticleId IdType="pubmed">23962497</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, et al. 2015. Serum MicroRNA profiles serve as novel biomarkers for the diagnosis of Alzheimer's disease. Dis. Markers 2015, 625659 (10.1155/2015/625659)</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/625659</ArticleId><ArticleId IdType="pmc">PMC4452867</ArticleId><ArticleId IdType="pubmed">26078483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A, et al. . 2014. Rapid isolation of extracellular vesicles from cell culture and biological fluids using a synthetic peptide with specific affinity for heat shock proteins. PLoS ONE 9, e110443 (10.1371/journal.pone.0110443)</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0110443</ArticleId><ArticleId IdType="pmc">PMC4201556</ArticleId><ArticleId IdType="pubmed">25329303</ArticleId></ArticleIdList></Reference><Reference><Citation>Saucier D, et al. . 2019. Identification of a circulating miRNA signature in extracellular vesicles collected from amyotrophic lateral sclerosis patients. Brain Res. 1708, 100&#x2013;108. (10.1016/j.brainres.2018.12.016)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.12.016</ArticleId><ArticleId IdType="pubmed">30552897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua YJ, Tang ZY, Tu K, Zhu L, Li YX, Xie L, Xiao HS. 2009. Identification and target prediction of miRNAs specifically expressed in rat neural tissue. BMC Genomics 10, 214 (10.1186/1471-2164-10-214)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-10-214</ArticleId><ArticleId IdType="pmc">PMC2688525</ArticleId><ArticleId IdType="pubmed">19426523</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Detloff MR, Miller KN, Santi L, Houl&#xe9; JD. 2012. Exercise modulates microRNAs that affect the PTEN/mTOR pathway in rats after spinal cord injury. Exp. Neurol. 233, 447&#x2013;456. (10.1016/j.expneurol.2011.11.018)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2011.11.018</ArticleId><ArticleId IdType="pmc">PMC3268901</ArticleId><ArticleId IdType="pubmed">22123082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoss AG, et al. . 2015. MiR-10b-5p expression in Huntington's disease brain relates to age of onset and the extent of striatal involvement. BMC Med. Genomics 8, 1&#x2013;14. (10.1186/s12920-015-0083-3)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-015-0083-3</ArticleId><ArticleId IdType="pmc">PMC4349621</ArticleId><ArticleId IdType="pubmed">25889241</ArticleId></ArticleIdList></Reference><Reference><Citation>Varendi K, Kumar A, H&#xe4;rma MA, Andressoo JO. 2014. MIR-1, miR-10b, miR-155, and miR-191 are novel regulators of BDNF. Cell. Mol. Life Sci. 71, 4443&#x2013;4456. (10.1007/s00018-014-1628-x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-014-1628-x</ArticleId><ArticleId IdType="pmc">PMC4207943</ArticleId><ArticleId IdType="pubmed">24804980</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Yui D, Luikart BW, McKay RM, Li Y, Rubenstein JL, Parada LF. 2012. Conditional ablation of brain-derived neurotrophic factor-TrkB signaling impairs striatal neuron development. Proc. Natl Acad. Sci. USA 109, 15 491&#x2013;15 496. (10.1073/pnas.1212899109)</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1212899109</ArticleId><ArticleId IdType="pmc">PMC3458400</ArticleId><ArticleId IdType="pubmed">22949667</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchman AS, Yu L, Boyle PA, Schneider JA, De Jager PL, Bennett DA.. 2016. Higher brain BDNF gene expression is associated with slower cognitive decline in older adults. Neurology 86, 735&#x2013;741. (10.1212/WNL.0000000000002387)</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002387</ArticleId><ArticleId IdType="pmc">PMC4763800</ArticleId><ArticleId IdType="pubmed">26819457</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadanand A, Janardhanan A, Vanisree AJ, Pavai T. 2018. Neurotrophin Expression in lymphocytes: a powerful indicator of degeneration in Parkinson's disease, amyotrophic lateral sclerosis and ataxia. J. Mol. Neurosci. 64, 224&#x2013;232. (10.1007/s12031-017-1014-x)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-017-1014-x</ArticleId><ArticleId IdType="pubmed">29247376</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x15a;lusarz A, Pulakat L. 2015. The two faces of miR-29. J. Cardiovasc. Med. 16, 480&#x2013;490. (10.2459/JCM.0000000000000246)</Citation><ArticleIdList><ArticleId IdType="doi">10.2459/JCM.0000000000000246</ArticleId><ArticleId IdType="pmc">PMC4449311</ArticleId><ArticleId IdType="pubmed">25689084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mundalil VM, et al. . 2014. Serum microRNA profiles in children with autism. Mol. Autism 5, 40 (10.1186/2040-2392-5-40)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2040-2392-5-40</ArticleId><ArticleId IdType="pmc">PMC4132421</ArticleId><ArticleId IdType="pubmed">25126405</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau MP, Bruse SE, David-Rus R, Buyske S, Brzustowicz LM. 2011. Altered microRNA expression profiles in postmortem brain samples from individuals with schizophrenia and bipolar disorder. Biol. Psychiatry 69, 188&#x2013;193. (10.1016/j.biopsych.2010.09.039)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2010.09.039</ArticleId><ArticleId IdType="pmc">PMC3038345</ArticleId><ArticleId IdType="pubmed">21183010</ArticleId></ArticleIdList></Reference><Reference><Citation>Leidinger P, et al. . 2013. A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 14, R78 (10.1186/gb-2013-14-7-r78)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2013-14-7-r78</ArticleId><ArticleId IdType="pmc">PMC4053778</ArticleId><ArticleId IdType="pubmed">23895045</ArticleId></ArticleIdList></Reference><Reference><Citation>dos Santos MCT, et al. 2018. miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. Oncotarget 9, 17 455&#x2013;17 465. (10.18632/oncotarget.24736)</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.24736</ArticleId><ArticleId IdType="pmc">PMC5915128</ArticleId><ArticleId IdType="pubmed">29707120</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallar&#xe8;s-Albanell J, Zome&#xf1;o-Abell&#xe1;n MT, Escaram&#xed;s G, Pantano L, Soriano A, Segura MF, Mart&#xed; E. 2019. A high-throughput screening identifies microRNA inhibitors that influence neuronal maintenance and/or response to oxidative stress. Mol. Ther. Nucleic Acids 17, 374&#x2013;387. (10.1016/j.omtn.2019.06.007)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.06.007</ArticleId><ArticleId IdType="pmc">PMC6626867</ArticleId><ArticleId IdType="pubmed">31302497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman II, Pedersen WA, Springer JE, Mattson MP. 1999. ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis. Exp. Neurol. 160, 28&#x2013;39. (10.1006/exnr.1999.7190)</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1999.7190</ArticleId><ArticleId IdType="pubmed">10630188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao N, Fang B, Lv H, Jiang Y, Chen F, Wang Z, Ma H. 2018. Upregulation of miR-199a-5p protects spinal cord against ischemia/reperfusion-induced injury via downregulation of ECE1 in Rat. Cell. Mol. Neurobiol. 38, 1293&#x2013;1303. (10.1007/s10571-018-0597-2)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-018-0597-2</ArticleId><ArticleId IdType="pubmed">29948551</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>